- Home
- ARR vs MESO Comparison
ARR vs MESO Comparison
Compare ARR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | MESO |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARR | MESO |
|---|---|---|
| Price | $17.41 | $19.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $17.00 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 3.0M | 252.9K |
| Earning Date | 10-22-2025 | 08-28-2025 |
| Dividend Yield | ★ 16.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $116,798,000.00 | $17,198,000.00 |
| Revenue This Year | $286.67 | $465.44 |
| Revenue Next Year | $74.00 | $75.37 |
| P/E Ratio | $26.44 | ★ N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $13.18 | $9.61 |
| 52 Week High | $19.34 | $22.00 |
Technical Indicators
Market Signals| Indicator | ARR | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 67.24 |
| Support Level | $16.79 | $17.48 |
| Resistance Level | $17.09 | $19.18 |
| Average True Range (ATR) | 0.30 | 0.64 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 75.81 | 89.21 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.